DV
Dividend Vision

COGT — Cogent Biosciences, Inc.

Cogent Biosciences, Inc. (COGT)

Total return is -14.6% over the past 8.4 years, 249.3 points behind SPY at 234.7%. Its deepest 1-year drawdown was 26.3%.

Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases, with its lead candidate bezuclastinib in Phase 3 trials for systemic mastocytosis and gastrointestinal stromal tumors, alongside earlier-stage programs targeting FGFR, ErbB2, and PI3K mutations. The company does not currently distribute dividends. Cogent Biosciences appeals to investors seeking exposure to clinical-stage biotech development rather than current income.

COGT key facts

Asset type
Stock
Asset class
Equity
Inception date
03/29/2018
Last close
$37.93
Market cap
$6,581,802,496
Average volume
1228832.0
Payment date
11/09/2020
Beta
0.329
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.19